SCHEMBL2471852

SCHEMBL2471852

CC(C)(COc1ccc(N)c2ccccc12)c1ccnc(OC(N)=O)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 10/20 0.38
IDO1 P14902 1/20 0.35
EP300 Q09472 1/20 0.35
KAT8 Q9H7Z6 1/20 0.35
SSTR4 P31391 1/20 0.32
MAPK14 Q16539 3/20 0.31
HCK P08631 2/20 0.31
MAPK12 P53778 2/20 0.31
SRC P12931 1/20 0.31
GSK3A P49840 1/20 0.31
NR3C2 P08235 1/20 0.30
MEN1 O00255 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
KLK3 P07288 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979511 0.80 AAK1 (0.46) AAK1MAPK14HCKMAPK12SRC
SCHEMBL12540671 0.78 AAK1 (0.48) AAK1NR3C2
SCHEMBL27739609 0.72 LRRK2 (0.36) NR3C2MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17143623 0.71 AAK1 (0.69) AAK1
SCHEMBL28486597 0.71 AAK1 (0.69) AAK1
SCHEMBL28841735 0.69 IDO1 (0.55) IDO1EP300KAT8MEN1KMT2A
SCHEMBL1978660 0.67 IDO1 (0.44) AAK1IDO1EP300KAT8MAPK14
SCHEMBL4838967 0.67 NOS3 (0.49) NR3C2KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1979745 0.65 RAB9A (0.46) AAK1MAPK14HCKMAPK12SRC
SCHEMBL1979750 0.65 RAB9A (0.46) AAK1MAPK14HCKMAPK12SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370428-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2016-08-10 EP disclosed
US-8299073-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-30 US disclosed
US-20110294812-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-12-01 US disclosed
EP-2370428-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2011-10-05 EP disclosed
WO-2010067131-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294812-A1 P38 MAP KINASE INHIBITORS MAPK1, MAP3K1, MAPK3 AAK1 322/4885IDO1 1844/4885EP300 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.